$4.630
-0.010 (-0.22%)收盘时
IMAB 资讯
IMAB 事件
I-Mab Rebrands as NovaBridge Biosciences
NovaBridge Biosciences has changed its corporate name from I-Mab to NovaBridge Biosciences. The change was overwhelmingly approved by shareholders at the Company's Extraordinary General Meeting held on October 24, 2025, and by the Company's Board of Directors. The Company's American Depositary Shares will trade on Nasdaq under the new name and a new ticker symbol, "NBP", effective at the opening of trading on October 30, 2025, replacing its current symbol "IMAB"/ The new corporate brand, including a new website, marks an important step in the Company's strategic transformation to a global biotechnology platform company committed to accelerating access to innovative medicines for patients worldwide. In connection with the name change and ticker symbol change, no action is required from current shareholders and the Company's CUSIP number will remain the same. Historical trading data of the Company's ADSs prior to October 30, 2025 may not yet be available on certain third-party websites and apps when searching for "NovaBridge Biosciences" and/or "NBP", in which case such data may temporarily be found under "I-MAB" and/or "IMAB". The Company intends to partner with leading innovators to identify and accelerate high-value assets. Our model integrates rigorous asset selection, bespoke translational strategies, and efficient clinical execution. With the backing of CBC Group, we leverage deep local insights and global capabilities to develop the most promising drug candidates across a range of therapeutic categories. The Company will utilize a "hub-and-spoke" model to create and advance specialized subsidiary companies which maintain operational focus and agility. By focusing each spoke on a specific asset or therapeutic area, the Company can optimally manage risk and create value through potential partnering transactions.
I-Mab Appoints Kyler Lei as CFO and Reveals Upcoming Acquisition of VIS-101
The company also announced the pending acquisition of VIS-101, a novel bifunctional biologic targeting VEGF-A and ANG2. The pending acquisition will be made by a newly formed subsidiary, Visara and is expected to be completed later this month. In addition, the company reaffirmed its previously announced givastomig investment plans as part of its new strategy. Kyler Lei has been named CFO of I-Mab. "We believe we are entering a new era of rapid growth in the global biotech economy, driven by greater innovation capability in China and Asia and a resurgence of investment in high growth international markets across Asia. With our new business model, we are uniquely positioned to strategically create significant value for patients and investors," said Mr. Fu Wei, Executive Chairman of I-Mab. "Through the strategic insight of our expanded Board, backing by CBC Group, Asia's largest dedicated healthcare asset management firm, and our dual listing strategy, I-Mab is ideally placed to partner with leading global innovators to identify and accelerate high-value assets. The proposed dual listing on both NASDAQ and HKEX is a key element of our global growth strategy. This move will enable us to broaden and diversify our investor base, and enhance trading liquidity and access to capital, while strengthening our presence with key stakeholders in the rapidly growing Asian market. 2025 has been a time of significant progress for I-Mab. Presentation of compelling Phase 1b givastomig combination data reinforced our confidence in its potential to be a best-in-class Claudin 18.2-directed therapy for gastric cancer and drove our plans to initiate a global randomized Phase 2 study, expected to begin in Q1 2026. In addition, the Company recently secured additional capital, and has attracted seasoned biotech executives to the Board of Directors and Scientific Advisory Board," said Sean Fu CEO of I-Mab. "With the strong foundation from our work on givastomig, and excellent progress this year, we are optimistic about moving forward with our new strategy. Our new global platform allows us to uphold our commitment to value creation by realizing the full potential of innovative medicines and improving the lives of patients."
I-Mab Plans Hong Kong IPO and Rebranding to NovaBridge Biosciences
I-Mab announced its new business model, focused on its global capabilities built to accelerate access to medicines and to enable broad strategic growth. The company announced its intention to pursue a Hong Kong IPO through dual listing on Nasdaq and Hong Kong Stock Exchange. The company intends to operate under the new name of NovaBridge Biosciences.
I-Mab reveals expedited funding for givastomig initiative
I-Mab announced accelerated investment in its lead program, givastomig, an investigational Claudin 18.2-directed bispecific antibody, including plans to initiate a global randomized Phase 2 study and additional Phase 1b cohorts. The Company also reiterated its expectations to report Phase 1b dose expansion data in Q1 2026. In addition, I-Mab announced leadership additions, including the appointment of Mr. Wei Fu as Executive Chairman, and the appointment of Dr. Sean Cao as Chief Business Development Officer. 1L Gastric Cancer Studies: Phase 1b dose expansion data expected in Q1 2026: Phase 1b dose expansion cohorts evaluating givastomig at two dose levels in combination with nivolumab and chemotherapy as a first-line treatment for patients with metastatic gastric cancers. Initiation of a global randomized Phase 2 study in 1L metastatic gastric cancers: The Company intends to initiate a randomized Phase 2 study in 1L metastatic gastric cancers evaluating givastomig in combination with nivolumab and chemotherapy versus nivolumab and chemotherapy alone. Progression free survival data are expected in 2027. Initiation of a 1L metastatic GC cohort for patients who do not qualify for checkpoint inhibitors or the existing approved CLDN18.2 1L GC therapy: The Company intends to initiate an additional Phase 1b cohort evaluating givastomig in combination with chemotherapy as a 1L treatment for patients with metastatic gastric cancers whose tumors express Claudin 18.2 in less than75% of cells and CPS scores less than1, known as patients. This population represents a significant unmet medical need since these patients are not eligible to receive the existing approved CLDN18.2-directed therapy or immunotherapies. The current standard of care is chemotherapy alone in this patient population. Expansion of Givastomig into Gastrointestinal Malignancies Characterized by CLDN18.2 Expression: 1L Pancreatic Ductal Adenocarcinoma: The Company intends to initiate an additional Phase 1b cohort in 1L, CLDN18.2-positive PDAC evaluating givastomig in combination with chemotherapy. 1L Biliary Tract Cancer: The Company intends to initiate an additional Phase 1b cohort in 1L, CLDN18.2-positive BTC evaluating givastomig in combination with a checkpoint inhibitor and chemotherapy. Investigator Initiated Trials Broaden Evaluation into Other Tumor Types in a Neoadjuvant Setting: Dr. Kohei Shitara, National Cancer Center Hospital East, Japan: A single arm study evaluating givastomig in combination with a checkpoint inhibitor and chemotherapy as a 1L neoadjuvant therapy for locally advanced, CLDN18.2-positive, resectable gastric cancers. Dr. Jeremy Kratz, University of Wisconsin, sponsored by the Department of Veterans Affairs: A single arm study evaluating givastomig in combination with chemotherapy as a 1L neoadjuvant therapy for CLDN18.2-positive, resectable pancreatic cancer. Governance and Leadership Updates: Mr. Wei Fu, the current Chairman of the Board of Directors has been appointed to the role of Executive Chairman by the Board. Additionally, the Board has appointed Dr. Sean Cao to the newly created role of Chief Business Development Officer (CBO). Dr. Cao will devote approximately half of his professional time to I-Mab to further support I-Mab's growth. Dr. Cao joins I-Mab from CBC Group and affiliates, bringing expertise in business development.
I-Mab Names Lenz and Liu to Board of Directors and Establishes R&D Committee
I-Mab announced the appointment of independent directors, Dr. Robert Lenz and Ms. Xin Liu, to its Board of Directors, effective as of August 22, 2025 and reiterated the appointment of independent director Dr. Sean Cao to the Board as of May 28, 2025. The Company also announced Lielie Zhang will be stepping down from the Board, effective as of August 20, 2025, with gratitude for his dedicated service. In addition, I-Mab announced the formation of a Research and Development Committee of the Board of Directors, R&D Committee, to be chaired by Dr. Robert Lenz, with Dr. Sean Cao and Dr. Sean Fu, Chief Executive Officer of I-Mab, as members. I-Mab will also expand its Scientific Advisory Board with the appointment of Dr. Ken Takeshita.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。